Proadrenomedullin (proADM) for clinical severity and prognosis in patients with pneumonia

Introduction: We need practical biomarkers to predict prognosis for pneumonia. ProADM recently found usefull for prognosis and developing clinical scores by many studies, while some claim opposite. We investigated value of proADM for prognosis in hospitalized Turkish patients and compare proADM with clinical scores (PSI, CURB-65) and other biomarkers (CRP, procalcitonin etc.). It was a validation study. Methods: 63 adult pneumonia patients were enrolled to the prospective study, performed at GATA Haydarpasa Training Hospital. Patients were followed for complications. Blood samples were taken initially and after antibiotic regimen and stored at -80 C. Elabscience elisa kit were used. Results: ProADM levels were dropped significantly after antibiotherapy (p Conclusion: We found no relation for proADM with pneumonia prognosis. Using proADM alone to predict prognosis and decide therapy setting makes no sense. In consideration of previous studies, proADM would be usefull as supplementary to clinical scores.